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A unique renal neoplasm characterized by eosinophilic cytoplasm and solid and cystic growth 
was recently reported in patients with Tuberosus Sclerosis Complex (TSC). We searched 
multiple institutional archives and consult files in an attempt to identify a sporadic counterpart. 
We identified 16 morphologically identical cases, all in females, without clinical features of 
TSC. The median age was 57 years (range 31-75 y). Tumors were yellow-gray and had a solid 
and cystic (12) or only solid appearance (4). Average tumor size was 50 mm (median, 38.5 mm; 
range 15-135 mm). Microscopically, the tumors showed solid areas admixed with variably sized 
macro and microcysts. The cells had voluminous eosinophilic cytoplasm with frequent 
cytoplasmic stippling and round to oval nuclei with prominent nucleoli (ISUP nucleolar grade 3). 
Scattered histiocytes and lymphocytes were invariably present. Thirteen of 16 patients were 
stage pT1; 2 were pT2, and 1 was pT3a. The cells demonstrated a distinct immunoprofile: 
nuclear PAX-8, diffuse (or focal) cytokeratin 20, patchy AMACR, but only rare focal cytokeratin 
7 or CD117 reactivity. Thirteen of 14 patients with follow-up were alive and without disease 
progression after 2 to 138 months (mean: 53 mo; median: 37.5 mo); 1 patient died of other 
causes. We propose that “eosinophilic, solid and cystic renal cell carcinoma”, which occurs 
predominantly in females and is characterized by distinct morphologic features, frequent 
cytokeratin 20 reactivity and indolent behaviour, represents a novel unrecognized subtype of 
renal cell carcinoma, which can be found associated with TSC, but also may occur sporadically.  
 
 
Running title: Eosinophilic Solid and Cystic Renal Cell Carcinoma 
 
Key words: Eosinophilic tumor; renal cell carcinoma; tuberous sclerosis; CK20; unclassified 





































































Recent studies have documented a unique type of renal neoplasm exhibiting eosinophilic 
cytoplasm and varying solid and cystic architectural growth, found predominantly in female 
patients with Tuberous Sclerosis Complex (TSC).(1, 2)  In contrast to the other patterns of renal 
cell carcinoma encountered in association with TSC, which were originally described in a 
sporadic setting (i.e. chromophobe-like and renal cell carcinoma with smooth muscle stroma), to 
our knowledge, these unique eosinophilic and cystic neoplasms have not been previously 
recognized or documented, other than in association with TSC. They are currently not included, 
or recognized as a provisional entity, in the 2013 International Society of Urological Pathology 
(ISUP) Vancouver Classification of renal tumors.(3)  
 
Although these neoplasms seem to demonstrate unique morphologic, clinical and 
immunohistochemical features, they have most likely been historically signed-out in routine 
diagnostic practice as “unclassified renal cell carcinoma” or descriptively designated 
“unclassified renal neoplasm (or carcinoma) with oncocytic or eosinophilic morphology” (or 
some combination of these descriptive terms).   
 
After encountering histologically identical neoplasms in a clinically sporadic setting, we initiated 
an international collaboration to identify and study a larger series of these unique renal tumors. 
Our aim was to establish and characterize their clinical and morphologic features, 
immunohistochemical profile, ultrastructural features, and to determine their clinical behaviour 




































































genomic hybridization in a limited number of cases, to evaluate for possible recurring genomic 
alterations. 
 
Material and Methods 
 An institutional Ethics Review was obtained for this study.  
 
Pathology evaluation 
We searched for renal neoplasms labelled in the initial sign-out as “unclassifed, oncocytic or 
eosinophilic” in multiple institutional archives and consult files of surgical pathologists with 
subspecialty interest in urologic pathology. Many of participating institutions represent centers 
with large in-house and consult uropathology practices. All cases were reviewed by two urologic 
pathologists, comparing the features with the index cases. One or multiple haematoxylin and 
eosin slides were available for review in all cases. Clinicopathologic and follow-up data were 
collected by review of the institutional records and by contacting the consulting pathologists. 
  
Immunochemical studies were carried out using a panel of primary antibodies, commonly used 
in urologic pathology, which included: PAX8, AMACR, CD10, CD117 (C-kit), EMA, CK7, 
CK20, CA9, AE1/AE3, CK8/18, and vimentin. The immunohistochemistry evaluation for 14 
cases was performed in 2 laboratories on representative blocks provided by the originating 
pathologist, and was read by two pathologists (KT, JMK). The immunohistochemistry and the 
evaluation of 2 additional cases was done by one pathologist in a separate laboratory (JIL). The 
immunostains for Hamartin and Tuberin were performed in one laboratory on the available 




































































considered if less than 5% of cells stained; ‘focal’ was if 5-25% cells were reactive, and 
‘positive’ was if >25% of cells were reactive.  
Electron microscopy evaluation was performed on two cases. Small pieces of formalin fixed 
paraffin embedded (FFPE) from cases #9 and #15 were deparaffinized and further  routinely 
processed for ultrastructural analysis. Semithin sections of epoxy embedded tissue were stained 
with toluidine blue, and examined by light microscopy. Ultrathin sections from representative 
area were cut, stained with uranyl acetate and lead citrate, and examined with a Jeol (Tokyo, 
Japan) JEM 1400 Transmission Electronic Microscope. 
 
Molecular karyotyping  
Molecular karyotyping was performed from FFPE tissue blocks in 3 cases (#2, #8 and #13). 
Eight sections, each 10 µm thick, were obtained of the FFPE tissue blocks. DNA was extracted 
and purified using the Ambion Recover All Total Nucleic Acid Isolation kit (Applied 
Biosystems, Carlsbad, California) following the manufacturer’s protocol. Briefly, the procedure 
entails deparaffinization with xylene, protease digestion, ethanol, and filter cartridge– based 
DNA isolation lowed by an on-filter RNase treatment and elution. Extracted DNA was 
quantified using Quant-iT PicoGreen ds DNA HS reagent and Qubit fluorometer (Invitrogen, 
Carlsbad, CA) following the manufacturer’s procedure. OncoScan Assay Kit Ver 3.0 was 
performed according to the manufacturer’s procedure. Briefly, the assay uses molecular 
inversion probes to analyze SNPs at >220,000 loci, as described previously.(4-6) Data generated 
by Affymetrix platform (probe signal intensity and genome location) were analyzed using Nexus 





































































Array comparative genomic hybridization (aCGH) 
Array comparative genomic hybridization (aCGH) was performed from FFPE tissue blocks in 3 
cases (#1, #2 and #10). A microarray: A CytoChip Focus Constitutional (BlueGnome Ltd, 
Cambridge, UK) was used for analysis, as previously described.(7) CytoChip Focus 
Constitutional uses BAC technology and covers 143 regions of known significance with 1 Mb 
spacing across a genome. Probes are spotted in triplicates. First, 400 ng of gDNA was labeled 
using the Fluorescent Labeling System (BlueGnome Ltd, Cambridge, UK). The procedure 
included Cy3 labeling of a test sample and Cy5 labeling of a reference sample. Commercially 
available reference of opposite sex was used in cases where no reference sample was available 
(MegaPool Reference DNA Male or MegaPool Reference DNA Female, Kreatech Diagnostics, 
Amsterdam, Netherlands). The labeled reference as well as the test sample were mixed, dried 
and hybridized overnight at 47 °C using ArrayIt hybridization cassettes (Arrayit Corporation, 
California, U.S.A.). Posthybridization washing was done using SSC buffers with increasing 
stringency. Dried microarrays were scanned with InnoScan 900 (Innopsys, France) at resolution 
5 μm. Image and Data analysis: Scanned images were analyzed and quantified by BlueFuse 
Multi software (BlueGnome Ltd, Cambridge, UK). BlueFuse Multi uses Bayesian algorithms to 
generate intensity values for each Cy5 and Cy3 labeled spot on the array according an 
appropriate .gal file. The reported changes were browsed and interpreted using BlueFuse Multi 
as well. Cut off values were set to log 2 ratio to -0.193 for loss and 0.170 for gain. 
 
Results 




































































The clinicopathologic features and the follow-up data are shown in Table 1. All 16 renal tumors 
were identified in females, demonstrating no clinical features of TSC. One patient (#12) had a 
sister with a Birt–Hogg–Dubé syndrome, but tested negative for folliculin (FLCN) gene 
mutation. Mean patient age was 57 years (range, 31-75y). A single tumor was identified in each 
affected kidney and no multifocality was found. Ten patients had partial nephrectomy and 6 had 
radical nephrectomy. There was no predilection for laterality (left kidney 7; right kidney 9). 
Thirteen of 16 cases (81%) were stage pT1 (pT1a in 9, pT1b in 4); 2 were pT2 (pT2a in 1and 
pT2b in 2) and 1 was pT3a. 
 
Follow-up was available for 14 of 16 patients. Thirteen of 14 patients were alive and without 
evidence of disease progression, after a follow-up ranging from 2 to 138 months (mean: 53 mo; 




Grossly, the tumors were yellow-gray to tan and the majority (12 of 16) showed a solid and 
cystic appearance, typically exhibiting a well-delineated mass with large macrocystic spaces, 
variable in size, and interspersed with solid nodules, as illustrated in Figure 1A. In some areas 
the cysts were separated by very thin cellular septa. The greatest tumor dimension was on 
average 50 mm (median, 38.5 mm; range 15-135 mm); however, the majority of tumors (10) 
measured up to 50 mm and only 2 exceeded 100 mm. The 4 cases that were exclusively solid, 





































































Microscopic findings  
On microscopy, the tumors showed variably sized solid nests and confluent sheets, typically 
admixed with large macrocysts, showing variably thick septa composed of eosinophilic cells 
(Figure 1B). A well-formed capsule was absent at the tumor periphery. The cysts varied in size, 
and were lined by cells showing hobnail arrangement with voluminous eosinophilic cytoplasm 
(Figure 1C). Focally, there were areas with microcystic appearance with smaller cysts set within 
larger nodules composed of eosinophilic cells (Figure 1D). In some tumors, the septa of the cysts 
were compressed between the solid nodules and were more difficult to appreciate (Figure 1E). 
Four smaller tumors showed exclusively solid growth (Figure 1F).  
 
The neoplastic cells had abundant eosinophilic cytoplasm and showed diffuse or tightly compact 
acinar or nested growth, and were typically admixed with small aggregates of histocytes and 
lymphocytes (Figure 2A-B). The cells had round to oval nuclei with focally prominent nucleoli 
(ISUP nucleolar grade 3). However, some cell variation was commonly present. Scattered cells 
had a peripheral rim of finely vacuolated or flocculent clear cytoplasm, focally showing marked 
size variation, variably coarse chromatin, and prominent nucleoli. Multinucleated cells were also 
common, focally forming clusters (Figure 2C). Within the solid foci, there were areas where the 
cells had less cytoplasm, imparting a more monotonous and basophilic appearance (Figure 2D). 
In examples with larger foci of basaloid cells, a nested or insular arrangement was seen (Figure 
2E). One of the very characteristic features was the presence of fine or coarse cytoplasmic 
stippling (basophilic to purple cytoplasmic granules) (Figure 2F). Although focal, rare cells also 




































































(Figure 2F inset). The cell morphology was identical in cases demonstrating only solid pattern, 
without the cystic component.  
 
In some cases, although a typical morphology was present in most of the sections, there were 
focal areas showing unusual features, such as clear cell change (Figure 3A), focal papillary 
arrangement (Figure 3B), tubular architecture (Figure 3C), marked intracytoplasmic 
vacuolization (Figure 3D) and vaguely chromophobe-like areas (Figure 3E). Rare calcifications, 
including psammoma bodies, were also noted, usually adjacent to the cystic lumina (Figure 3F).  
 
Immunohistochemistry 
The complete immunohistochemistry (IHC) results are shown in Table 2. The neoplastic cells 
typically demonstrated nuclear PAX-8 reactivity (100%) (Figure 4A), patchy cytoplasmic 
AMACR staining (Figure 4B), and usually diffuse (or less often focal) cytokeratin (CK) 20 
reactivity (Figures 4C and 4D), but showed only minimal focal or no staining for cytokeratin 7 
(Figure 4E) or CD117 (Figure 4F). Of note, the 2 cases that were considered CK20 negative did 
show rare isolated positive cells. EMA was either negative or focally positive and cytokeratins 
(AE1/AE3 and CK8/18) were positive or focally positive in great majority of cases. Vimentin 
was positive in 10/13 cases, CD10 was diffusely or focally positive in 10/13 cases, while CA9 
was positive in 2/10 cases (cytoplasmic only). Tuberin was retained, while Hamartin was lost in 
all tested cases (10/10). The staining was also performed for several additional antibodies, but 
due to limited number of evaluated cases, they are not included in Table 2. The results for the 
additional antibodies are as follows: HMB45/Melan A - negative in 6/6; TFE-3 - negative in 4/4 








































































The tissue was partly damaged by fixation and deparaffinization. Ultrastructural analysis 
however revealed polygonal cells organized in solid nests and tightly packed acinar structures 
with focally visible lumina (Figure 5A-B). Rudimentary intercellular junctions were present as 
well as relatively scarce microvilli on the luminal surface (Figure 5B). Most of the cells had oval 
nuclei with shallow invaginations and some of them also had one prominent nucleolus (Figure 
5C). Although cytoplasmic organelles were poorly preserved, abundant rough endoplasmic 
reticulum, accompanied by granular material, was visible in the majority of neoplastic cells 
(Figure 5C-D). Larger amounts of glycogen particles, lipid droplets or complex vesicles were not 
found.  
 
Molecular karyotyping  
Molecular karyotyping profiles were successfully established for the 3 evaluated cases across the 
whole genome and are illustrated in Figure 6 A. Loss of heterozygosity (LOH) was found for all 
three cases at 16p11.2 –1 (22 genes) and at Xq11.1-12 LOH (20 genes). Cases #8 and #13 also 
revealed LOH on 11p11.2-1 (10 genes). 
In particular, cases #2 and #8 revealed similar molecular alterations. Copy number (CN) gains 
were found at 1p13.3, 7p22.3 – 7q36.3 (nearly whole chromosome), 7p11.2 (high CN gain), 
10q23.31, 13q14.2, and 16p13.3 – 16q24.3 (nearly whole chromosome). CN losses were found at 




































































Xq23 – Yp11.32 (end of X telomere).  
 
Array comparative genomic hybridization (aCGH) 
aCGH was successfully carried out only in 1 (case #1) of the 3 evaluated cases (#1, #2 and #10). 
In this case, a gain of chromosome 16 was revealed, as illustrated in Figure 6B. The status of the 
remaining chromosomes was normal.  
 
Discussion 
We propose that the renal neoplasm described herein as “eosinophilic, solid, and cystic renal cell 
carcinoma” (ESC RCC) is a distinct subtype of renal epithelial neoplasm. The key features of 
ESC RCC are summarized in Table 3. In this study, it was found only in female patients and 
showed consistent gross and microscopic features, frequent CK20 reactivity, gain of 
chromosome 16, and an indolent clinical behaviour. While these ESC RCCs are virtually 
identical to the neoplasms previously documented in a subset of TSC patients,(1, 2) none of 
these current patients had any clinical or pathologic signs of TSC. The true incidence of ESC 
RCC is difficult to estimate, but the fact that we were able to identify only 1 to 2 cases in the 
majority of participating institutions with large uropathology practices, indicates that it is indeed 
very rare.  
 
Two recent studies documented renal neoplasms showing identical morphology to those 
presented in this current study, but in association with TSC.(1, 2) We first learned of this 




































































man with TSC and bilateral renal lesions, including multiple minute angiomyolipomas, cortical 
cysts, and 4 separate RCCs of unclassified type.(1) The carcinomas shared distinctive 
morphological features, including sheet-like, glandular, trabecular, or cystic architecture and 
abundant granular eosinophilic cytoplasm. One of the 4 tumors, labelled “RT1” (morphology 
illustrated in their Figure 1, B-D (1)), in our view, is identical to the cases described herein. It 
demonstrated solid areas composed of eosinophilic epithelioid cells arranged in acinar formation. 
In many areas, higher grade nuclei were present (Fuhrman grade 3) and multinucleated cells 
were seen in clusters, as seen in the cases presented in the current study.  
 
Prompted by an index case seen in consultation, which demonstrated similar morphology to renal 
neoplasm “RT1” described by Schreiner et al, Guo et al collected a series of 57 separate renal 
cell carcinomas (RCC) in 18 patients with TSC and described three distinct morphologies.(2) 
They documented 6 RCCs (11% of all evaluated tumors), demonstrating “granular eosinophilic-
macrocystic morphology’, which were essentially identical to the tumors described in the present 
study. This patient group actually represented 33% (6/18) of all included TSC patients, and all 6 
were females, with a single tumor per kidney, as in the present study. Of the remaining cases, 17 
RCCs (30%) had features similar to the tumors previously described as “renal 
angiomyoadenomatous tumor” or “RCC with smooth muscle stroma”, while 34 RCCs (59%) 
showed features similar to chromophobe RCC (or hybrid oncocytic tumors); multifocality was 
frequent in these two groups. Several of the co-authors of the current study participated in the 
Guo et al study (2), and had an opportunity to evaluate and compare the 6 tumors with 
“eosinophilic-macrocystic morphology” (illustrated in Figure 3 by Guo et al (2)), to the ones 




































































both groups, those associated with and without TSC, are pathologically identical. Moreover, all 6 
cases associated with TSC showed similar IHC profile: PAX8 positive, CK7 only focally 
positive; negative for CA9, CD117 and HMB45. Unfortunately, CK20 reactivity, one of the key 
IHC findings in the present study, was not evaluated by Guo et al.(2)  We have retrospectively 
evaluated 2 of the originally reported cases and both show strong patchy cytoplasmic 
immunoreactivity for CK20 (unpublished data), similar to the sporadic cases presented herein. 
Although CK20 is not routinely investigated or included in an immunopanel to evaluate renal 
tumors, we found it to be quite helpful in supporting the diagnosis of this tumor, as 14 of 16 
(88%) cases in this series showed either diffuse (69%) or focal (19%) cytoplasmic reactivity for 
CK20. Admittedly, this finding was completely serendipitous, as the stain had been performed at 
the time of original evaluation on the archived index case. In our experience, CK20 is typically 
negative in the common renal neoplasms that may be considered in the differential diagnosis of 
ESC RCC.  
 
In addition to the common association with AML, there are multiple additional reports of renal 
neoplasms with variable morphologies seen in association with TSC (mostly as case reports or 
small series), including clear cell, papillary, chromophobe and unclassified RCC, as well as cases 
labelled “oncocytoma”.(8-13) We could not find any tumors with morphologic features similar 
to the ones described herein in these previous studies.(8-13)  Another recent series of RCCs in 
TSC (14) did not document any tumors with this unique eosinophilic and cystic morphology. 
  
TSC results from mutations in 1 of 2 interacting gene products, hamartin, associated with TSC1 




































































16p13). Although it is known that they are expressed and co-localized in most normal human 
tissues, including the proximal and distal renal tubules and collecting ducts, there are some 
differences in expression within different types of renal tubules.(15) However, the expression of 
hamartin and tuberin has not been well studied in renal tumors and they are not used as part of 
the routine IHC evaluation in this setting. Prompted by the previous association of these gene 
products with TSC, we tested 10 of 16 available cases by IHC, and found that tuberin was 
retained, while hamartin was lost in all tested cases. The significance of this finding is uncertain 
at this time. Of note, we have also found that tuberin was positive in 4/4 of ESC RCC associated 
with TSC, while hamartin was negative in 3/4 cases (1 was weak positive) (unpublished data). It 
is interesting to note that the aCGH showed a gain of chromosome 16 in case #1 and that 
molecular karyotyping of cases #2 and #8 also showed CN gain affecting nearly the whole 
chromosome 16 (16p13.3 – 16q24.3), which encompasses the tuberin encoding region Although 
the patients in this study had no clinical evidence of TSC, it is well known that TSC has a high 
de novo mutation rate, and such an event cannot be completely ruled out.(16) Although genetic 
testing for TSC was not done in the patients included in the study (which is a study limitation), 
even the molecular genetic testing for TSC, often done in specialized centers, appears to be 
complex and imperfect. For example, it was reported that 16.9% of patients who met the clinical 
criteria for TSC had no identified mutation by standard genotyping.(16) Additionaly, none of the 
patients in this study had any AMLs found in the adjacent renal parenchyma, which are 
invariably seen in patients with classic TSC. 
 
The molecular karyotyping results, although available on only 3 of 16 cases, revealed a unique 




































































found in 2 of 3 cases (#8 and #13).  Cases #2 and #8, in particular, showed a distinct pattern of 
CN gains (1p, 7p, 10q, 13q, 16p and 16q) and CN losses (19p, 19q, Xp, and Xq). Similarly, 
aCGH showed a gain of chromosome 16. These results provide additional evidence supporting a 
distinct genetic profile in these neoplasms that is different from the well-characterized renal 
neoplasms with known recurrent genetic alterations. 
 
The differential diagnosis of ESC RCC includes other renal tumors with eosinophilic cytoplasm, 
such as oncocytoma, eosinophilic variant of chromophobe RCC, SDH deficient RCC, MiT 
translocation type RCC, and epitheliod AML. Other more common RCCs, such as clear cell 
RCC, particularly of higher grade, and the solid variant of papillary RCC, primarily the 
oncocytic type, may also be considered in the differential. Some of these indeed may show a 
more cystic appearance (such as clear cell carcinoma), but the features of the ESC RCC, as 
described herein, are sufficiently distinct in our opinion, to distinguish them from the other renal 
tumors. Both oncocytoma and eosinophilic chromophobe RCC typically have a more uniform 
architecture, without a macrocystic component, and both also show more uniform cytology. 
While rare focal areas in ESC RCC did superficially resemble chromophobe RCC, well-
developed perinuclear halos and more irregular nuclear membranes were not a prominent 
feature. Both oncocytoma and eosinophilic chromophobe RCC are also typically reactive for 
CD117 (C-kit), which was uniformly negative in ESC RCC. In addition to CK20, which should 
be negative in both oncocytoma and chromophobe RCC, CK7 is typically diffusely positive in 
chromophobe RCC, and either negative or only focally reactive in minority of ESC RCC, similar 
to oncocytoma. SDH deficient RCC, is a recently characterized, distinct and rare renal neoplasm, 




































































Although it may show focal microcystic changes, macrocysts were not documented. SDH 
deficient RCC typically exhibits uniform low-grade cytology, with cytoplasmic vacuoles, and 
eosinophilic or flocculent cytoplasm. Two cases in the present study (#1 and #2) were also tested 
and demonstrated positive IHC staining for SDHA and SDHB (SDHB is typically negative in 
SDH deficient RCC). Although rare examples of MiT translocation type RCC (most often Xp11) 
may show mostly eosinophilic morphology, they more often show clear cell morphology with 
cells exhibiting a voluminous cytoplasm, typically not seen in ESC RCC. MiT translocation type 
RCC also typically show papillary and nested architecture. TFE3 was also tested in 4 cases by 
IHC in this study and it was consistently negative (1 case also tested negative by FISH). 
Epithelioid AML is another relatively rare tumor, which despite the morphologic similarities 
with ESC RCC, in many cases demonstrates more prominent pleomorphism. More importantly, 
epithelioid AML does not label for cytokeratins, while it is positive for HMB45/Melan A, which 
is the opposite phenotype of ESC RCC. In addition, the demonstration of nuclear PAX-8 
expression essentially excludes AML in our experience. Higher grade clear cell RCCs may also 
show eosinophilic morphology and macrocysts, but they typically have a delicate vascular 
pattern, which was not seen in ESC RCC. Clear cell RCC also does not label for CK20, but 
typically have strong membranous reactivity for CA9, opposite of the pattern seen in ESC RCC 
(CK20 positive, CA9 negative). Additionally, it is not entirely uncommon for the epithelial cyst 
lining in cystic areas of clear cell RCC to show strong immunoreactivity for CK7, another 
finding not seen in ESC RCC.(18) Although the oncocytic variant of papillary RCC typically 
demonstrates predominantly papillary growth, less frequent solid patterns are also well-
described.(19) Papillary architecture was present only focally in 1 case of ESC RCC. Oncocytic 




































































negative immunophentype. Finally, the cytoplasmic stippling, a characteristic feature of ESC 
RCC, to our knowledge, is not reported in any of the recognized renal neoplasms and none of the 
renal tumors listed in the differential have such a striking female predominance. The key features 
and the immunostains that can be used to distinguish ESC RCC from other renal tumors are 
shown in Table 4. 
 
Although all tumors in this study with available clinical follow-up demonstrated an indolent 
clinical course, with no evidence of either recurrence or metastatic disease, the limited number of 
studied cases so far, precludes a definitive confirmation of its benign nature. Additional studies 
with longer follow-up would be needed to confirm their outcome over an extended clinical 
course. While the label “uncertain malignant potential” has also been used to designate tumors of 
controversial and debatable biologic nature, we decided to designate these tumors as 
“eosinophilic, solid and cystic RCC” (ESC RCC), in a descriptive manner, which, in our view 
adequately captures the tumor morphology. Other recently described specific subtypes of 
indolent renal neoplasia have followed the same approach with designation of renal cell 
carcinoma and an accompanying descriptive name (e.g. mucinous tubular and spindle cell RCC, 
clear cell papillary RCC, or tubulocystic RCC).(3) We considered using the descriptor 
“macrocystic” instead of “cystic”, but favoured “cystic”, because it is a more general term that 
incorporates both the macro and the microcystic component. Should additional information 
become available in the future to better characterize the nature of this tumor, appropriate 





































































In conclusion, ESC RCC appears to be a unique renal neoplasm that is predominantly found in 
females, and shows distinct morphologic features, frequent CK20 reactivity, gain of chromosome 
16, and indolent clinical behaviour. They appear histologically identical to a subset of renal 
neoplasms seen in TSC patients, but in this study, they were found in a sporadic setting. 
Awareness of the clinical, morphologic and immunophenotypic features of this novel renal 
neoplasm will increase its recognition and will allow surgical pathologists to re-evaluate similar 
renal tumors, previously considered “unclassified”.  
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Figure 1: Typical architectural patterns in eosinophilic, solid and cystic renal cell carcinoma. A) 
The macroscopic features include a well-delineated mass with large macrocystic spaces 
interspersed with tan solid nodules.  B) Histologically, the dilated macrocystic spaces are lined 
by neoplastic cells characterized by voluminous eosinophilic cytoplasm and C) a prominent 
hobnail arrangement. D) Some foci have a microcystic appearance with smaller cysts set within 
large nodules of the eosinophilic cells. E) In some tumors, the septa of the cysts (arrows) are 
compressed between solid nodules and are more difficult to appreciate, while F) rare examples 
have a completely solid growth. 
Figure 2: Typical cytologic features in eosinophilic solid and cystic renal cell carcinoma. A) The 
neoplastic cells have abundant eosinophilic cytoplasm and admixed aggregates of histocytes and 
lymphocytes are invariably present. B) The neoplastic cells had tightly compact acinar or nested 
growth. C) Multinucleated cells are also common. D) Within the solid foci, some cells have less 
cytoplasm imparting a more monotonous and basophilic appearance (arrows). E) In examples 
with large foci of basaloid cells, a nested/insular arrangement may be seen. F) The cytoplasm 
characteristically shows fine (small arrow) or coarse stippling (large arrow). Rarely, there were 
cells with larger, eosinophilic to purple cytoplasmic globules, surrounded by a delicate clear rim 
(inset).  
Figure 3: Unusual features in eosinophilic, solid and cystic renal cell carcinoma include: A) 
focal clear cell change; B) focal papillary change (arrows show residual septa of more typical 
macrocysts); C) tubular architecture; D) marked intracytoplasmic vacuolization; E) 




































































Figure 4: Typical immunophenotypic features of eosinophilic, solid and cystic renal cell 
carcinoma: A) Nuclear PAX-8 reactivity; B) Patchy cytoplasmic AMACR staining; C) Diffuse 
or D) patchy cytokeratin 20 immunoreactivity; E) No staining with cytokeratin 7 or F) CD117. 
Figure 5: Electron micrographs of neoplastic cells of eosinophilic, solid and cystic renal cell 
carcinoma.  A) Polygonal cells arranged in solid nests. B) Structures with focal lumina and 
visible short microvilli. C-D) Abundant rough endoplasmic reticulum accompanied by granular 
material was visible in the majority of neoplastic cells. The nuclei were oval with shallow 
invaginations and some of them also had one prominent nucleolus (C, upper right corner). 
Figure 6: A) Molecular karyotyping profiles showing copy number (CN) gains and losses from 3 
cases (#2, #8 and #13) (blue denotes CN gains; red denotes CN loses); B) aCGH result from case 









































































Table 1: Clinicopathologic features and follow-up of eosinophilic, solid and cystic renal cell carcinoma (ESC RCC) 






Gross Stage ISUP grade Status Follow-up 
(months) 
1 R 69 F 18 Partial Tan, solid 
and cystic 
pT1a 3 ANED 138 
2 L 74 F 53 Radical Tan, solid 
and cystic  
pT1b 3 DOC 14 
3 R 54 F 44 Partial Tan, solid 
and cystic 
pT1a 3 ANED 6 
4 R 49 F 15 Partial Tan, solid pT1a 3 NA NA 
5 L 75 F 58 Partial Tan, solid 
and cystic 
pT1b 3 ANED 15 
6 L 63 F 19 Partial Brown-
yellow 
pT1a 3 ANED 39 
7 R 56 F 65 Partial Tan, solid 
and cystic 
pT1b 3 ANED 36 
8 R 47 F 30 Radical Tan, solid pT1a 3 ANED 8 
9 L 66 F 80 Radical NA pT2a 3 ANED 60 
10 R 66 F 135 Radical NA pT3a 3 ANED 130 
11 R 50 F 20 Partial Tan, solid 
and cystic 
pT1a 3 ANED 32 
      12* L 44 F 45 Partial Tan, cystic 
and solid 
pT1b 3 ANED 53 
13 L 45 F 33 Radical Tan, solid pT1a 3 NA NA 
14 L 31 F 130 Radical NA pT2b 3 ANED 144 
15 R 53 F 30 Partial NA pT1a 3 ANED 75 
16 R 69 F 18 Partial Tan solid pT1a 3 ANED 2 
ANED = alive no evidence of disease; NA = not available; DOC = died of other causes 
* Sister with Birt-Hogg-Dubé syndrome; patient tested negative for FLCN (folliculin) mutation
Tables 1-4
Table 2. Immunohistochemistry results for eosinophilic, solid and cystic renal cell carcinoma (ESC RCC) 
 
Patient Pax8 AMACR CD10 CD117 EMA CK7 CK20 CA9 AE1/AE3 CK8/18 Vimentin Hamartin Tuberin 
1 + +/- - - +/- - + NA +/- + - - + 
2 + + + - +/- - +/- NA +/- + + - + 
3 + - - NA NA +/- + + - + - NA NA 
4 NA +/- NA NA - - + - - + +/- - + 
5 + NA NA NA NA - + NA NA NA NA - + 
6 + +/- NA NA NA +/- + - NA NA NA - + 
7 + +/- + - - - +/- + +/- + - - + 
8 + +/- +/- - - - + - +/- + + - + 
9 + - + - - - + - - +/- + NA NA 
10 + - + - +/- - - - +/- + + NA NA 
11 + +/- - +/- - - - - +/- +/- + - +/- 
12 + +/- +/- - +/- +/- + NA +/- +/- + - + 
13 + +/- +/- - - - + - + + + - + 
14 + + +/- - - - +/- NA + + + NA NA 
15 + +/- + - - +/- + - + + + NA NA 
16 + + +/- - NA - + NA NA NA NA NA NA 
Percent pos* 100% 80% 77% 8% 33% 25% 88% 20% 77% 100% 77% 0% 100% 
‘+ ‘= positive, '-' = negative, '+/-' = focal; 'NA' = not available  
* Percent positive includes both focal and diffuse positive cases, excluding cases with unavailable result
Table 3: Summary of the key features of eosinophilic, solid and cystic renal cell carcinoma (ESC RCC) 
 
Clinical Females only, usually low stage, good prognosis 
 
Gross  Solid and cystic or solid (minority), yellow-gray, single tumors 
 
Light microscopy  Architecture: Solid and cystic, diffuse or tightly compact acinar or nested 
growth, capsule absent  
 
Cytology: Eosinophilic voluminous cytoplasm with stippling, round to oval 
nuclei, prominent nucleoli (ISUP nucleolar grade 3). Scattered foamy 
histyocytes, lymphocytes and multinucleated cells. Hobnail cells line the 
cysts. 
 
Immunohistochemistry Positive: PAX-8, CK20, Vimentin, AMACR (+/-), CD10 (+/-), Tuberin 
Negative: CA9, CD117, CK7, HMB-45, Hamartin 
 
Electron microscopy Abundant rough endoplasmic reticulum 
 
Molecular karyotype LOH: 16p and Xq (3/3 cases); 11p (2/3 cases) 
CN gains: 1p, 7p, 10q, 13q, 16p (2/3 cases) 
CN losses: 19p, 19q, Xp, Xq (2/3 cases) 
 
aCGH  gain of Chr 16 
 
  
LOH = loss of heterozigosity; CN = copy number 
 
Table 4: Key features and immunostains helpful in distinguishing eosinophilic, solid and cystic renal cell 




Key distinguishing features 
 
Immunohistochemistry 
Eosinophilic, solid and 
cystic RCC 
Only females, solid and cystic growth, 
voluminous eosinophilic cytoplasm, 
cytoplasmic stippling, usually low stage 
 
CK20+, CK7-/+, CD117-, 




Solid and uniform architecture, irregular 
nuclear membranes, perinuclear halos 
  
CD117+, CK7+, CK20- 
 




Epithelioid cells which may be pleomorphic, 
lacks macrocysts 
PAX8-, HMB45+, PanCK-, 
CK7-, CK20- 
 




Clear cell RCC, 
eosinophilic morphology 
Focal clear cell areas, delicate vasculature, may 




MiT translocation RCC Large cells with clear (or eosinophilic) 
morphology, focal papillary and nested growth, 
lack cysts (usually) 
 
TFE3+, TFEB+, HMB45+ 
SDH-deficient RCC Lacks macrocysts, uniform low-grade 
oncocytic cells with flocculent cytoplasms, 
cytoplasmic vacuoles 
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